Innovative Medicines Initiative and antibiotic resistance

The Lancet Infectious Diseases

Volumn 15, Issue 12, 2015, Pages 1373-1375

  Kostyanev, Tomislav ^a   Bonten, Marc JM ^b   O'Brien, Seamus ^c   Goossens, Herman ^a,d  

^a UNIVERSITY OF ANTWERP   (Belgium)

^b UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

^c ASTRAZENECA   (United Kingdom)

^d ANTWERP UNIVERSITY HOSPITAL   (Belgium)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBIOTIC AGENT; MONOCLONAL ANTIBODY; NEW DRUG;

ANTIBIOTIC RESISTANCE; ANTIMICROBIAL THERAPY; BRONCHIECTASIS; CLINICAL RESEARCH; CLINICAL TRIAL (TOPIC); CYSTIC FIBROSIS; DRUG INDUSTRY; DRUG RESEARCH; ECONOMICS; EXPERIMENTAL THERAPY; GRAM NEGATIVE BACTERIUM; GRAM NEGATIVE INFECTION; INFECTION PREVENTION; NOTE; PRIORITY JOURNAL; PSEUDOMONAS INFECTION; PUBLIC-PRIVATE PARTNERSHIP; STAPHYLOCOCCUS AUREUS; STUDY DESIGN; TRANSLATIONAL RESEARCH; EUROPE; HUMAN; MULTIDRUG RESISTANCE; SYNTHESIS;

DRUG INDUSTRY; DRUG RESISTANCE, MULTIPLE, BACTERIAL; DRUGS, INVESTIGATIONAL; EUROPE; HUMANS; PUBLIC-PRIVATE SECTOR PARTNERSHIPS;

EID: 84965083893     PISSN: 14733099     EISSN: 14744457     Source Type: Journal    
DOI: 10.1016/S1473-3099(15)00407-7     Document Type: Note

References (5)

1. 1 Carlet, J, Collignon, P, Goldmann, D, et al. Society's failure to protect a precious resource: antibiotics. Lancet 378 (2011), 369–371.
2. 2 WHO European Strategic Action Plan on Antibiotic Resistance. http://www.euro.who.int/__data/assets/pdf_file/0008/147734/wd14E_AntibioticResistance_111380.pdf?ua=1, 2011 (accessed May 11, 2015).
3. 3 Schäberlee, T, Hack, I, Overcoming the current deadlock in antibiotic research. Trends Microbiol 22 (2014), 165–167.
4. 4 Antibiotic armageddon in UK and Europe by 2025. ESCMID Press Release. https://www.escmid.org/fileadmin/src/media/PDFs/2News_Discussions/Press_activities/ECCMID_2015/ESCMID_one_million_deaths_UK_consumer.pdf, April 21, 2015 (accessed May 11, 2015).
5. 5 Kostyanev T, Bonten MJM, O'Brien S, et al. The Innovative Medicines Initiative (IMI) New Drugs for Bad Bugs (ND4BB) programme—European public–private partnerships for the development of new strategies to tackle antibiotic resistance. J Antimicrob Chemother (in press).